Recently, Janouskova et al. reported prostate cancer–associated SPOP mutants impaired its binding to BET proteins, leading to the reduced proteasomal degradation and accumulation of these proteins in prostate cancer cell lines and patient specimens, which subsequently causes resistance to BET inhibitors (Janouskova et al., 2017). The gene discussed is SPOP; the disease is prostate cancer.